FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Gly topics
Door Assembly
Swimming Goggles
Transverse
Alkoxylate
Fluoropolymer
Air Cleaning
Rotor Shaft
Aspect Ratio
Disconnect
Synchronization
Remote Control
Ethylene Glycol
Surfactant
Combustion
Steviol Glycosides

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Gly patents



      
           
This page is updated frequently with new Gly-related patent applications. Subscribe to the Gly RSS feed to automatically get the update: related Gly RSS feeds. RSS updates for this page: Gly RSS RSS


Production of fucosylated glycoproteins

Novartis Ag

Production of fucosylated glycoproteins

Production of fucosylated glycoproteins

Dsm Ip Assets B.v.

Yeast strains engineered to produce ethanol from acetic acid and glycerol

Date/App# patent app List of recent Gly-related patents
06/25/15
20150179145
 Method and a system for displaying product information on electronic labels patent thumbnailMethod and a system for displaying product information on electronic labels
The present invention concerns a method for displaying product information on at least one electronic label having a graphic display and a data reception unit, characterized in that it comprises the steps of: (a) generating, at a server connected to the label, an individual glyph corresponding to each different character or symbol of the product information; (b) generating at least a display script comprising reference and position data of said glyphs in the product information; (c) transmitting the display script to the label; (d) broadcasting the individual glyphs; (e) selecting and loading in the label individual glyphs corresponding to the reference data comprised in the display script; and (f) displaying the selected and loaded individual glyphs according to the position data comprised in the display script. The present invention also concerns a server, an electronic label and a server thereof..
Store Electronic Systems
06/25/15
20150177180
 Electrode and use thereof patent thumbnailElectrode and use thereof
The application relates to an electrode for use in the electrochemical detection of target species, and in particular for the detection of insulin. The application enables insulin to be detected with high selectivity and with a detection limit in the picomolar range or lower.
Isis Innovation Limited
06/25/15
20150176044
 Production of fucosylated glycoproteins patent thumbnailProduction of fucosylated glycoproteins
Described herein are compositions including filamentous fungal cells, such as trichoderma fungal cells, having reduced protease activity and expressing fucosylation pathway. Further described herein are methods for producing a glycoprotein having fucosylated n-glycan, using genetically modified filamentous fungal cells, for example, trichoderma fungal cells, as the expression system..
Novartis Ag
06/25/15
20150176032
 Yeast strains engineered to produce ethanol from acetic acid and glycerol patent thumbnailYeast strains engineered to produce ethanol from acetic acid and glycerol
The present invention relates to processes for producing ethanol from lignocellulosic hydrolysates comprising hexoses, pentoses and acetic acid, whereby genetically modified yeast cells are use that comprise an exogenous gene encoding an acetaldehyde dehydrogenase and a bacterial gene encoding an enzyme with nad+-linked glycerol dehydrogenase activity. The process is further characterised in that glycerol is present in or fed into the culture medium, whereby the modified yeast cell ferments the hexoses, pentoses, acetic acid and glycerol to ethanol.
Dsm Ip Assets B.v.
06/25/15
20150176020
 Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases patent thumbnailMammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases
The present invention relates to non-mammalian β-1,4-galactosyltransferases that can be used in their wild-type or in modified forms. The invention further relates to transformed plants and plant cells expressing non-mammalian β-1,4-galactosyltransferases and methods to produce glycoproteins with altered and preferably mammalian-type glycosylation.
Stichting Dienst Landbouwkundig Onderzoek
06/25/15
20150175979
 Ptprs and proteoglycans in autoimmune disease patent thumbnailPtprs and proteoglycans in autoimmune disease
Provided herein, inter alia, are ptprs de-clustering agents and compositions and kits comprising the agents. Provided are methods of modulating extracellular matrix or decreasing fibroblast activity in a subject.
La Jolla Institute For Allergy And Immunology
06/25/15
20150175969
 Polypeptide, scaffold composition, composition for cartilage tissue restoration, composition for cartilage cell culture, and composition for promoting glycosaminoglycan production patent thumbnailPolypeptide, scaffold composition, composition for cartilage tissue restoration, composition for cartilage cell culture, and composition for promoting glycosaminoglycan production
A polypeptide having an amino acid sequence in which the number of rgd sequences contained per molecular weight of 10 kda is not less than 0.30; the number of gfpger sequences contained per molecular weight of 10 kda is not less than 0.15; and the number of gvmgfp sequences contained per molecular weight of 10 kda is less than 0.30; is provided. A scaffold composition, a composition for repairing a cartilage tissue, a composition for culturing cartilage cells, and a composition for promoting glycosaminoglycan production, which compositions contain the above polypeptide, are also provided..
Fujifilm Corporation
06/25/15
20150175955
 Cryopreservation tools and methods patent thumbnailCryopreservation tools and methods
Provided herein are methods for the cryopreservation of stem cells and/or progenitor cells, comprising the steps of (a) contacting stem cells and/or progenitor cells with a cryopreservation medium, said cryopreservation medium comprising between 4 v/v % and 25 v/v % of propylene glycol and between 1.0 w % and 10 w % of a sugar; and (b) slow-freezing said cells, thereby obtaining a frozen composition comprising said cells and said cryopreservation medium.. .
Fertipro N.v.
06/25/15
20150175865
 Dehazing agent patent thumbnailDehazing agent
A dehazing agent includes a polyethylene glycol compound of 6˜27 wt %, a modified organic polysiloxane mixture of 45˜60 wt % and alcohol. The surface of the article being sprayed or coated with the dehazing agent becomes hydrophilic such that the contact angle of a drop of water on the article is less than 10 degrees.
National Taiwan University
06/25/15
20150175810
 Dissolvable films and methods of using the same patent thumbnailDissolvable films and methods of using the same
The present invention provides dissolvable films for customizing art materials, such as inks, paints, and modeling doughs. The invention also provides methods and kits for delivering artistic effects to art materials.
Crayola, Llc
06/25/15
20150175784

Polaymine curable, highly saturated nitrile rubber composition


Disclosed is a polyamine curable, highly saturated nitrile rubber composition having excellent cold resistance in the presence of a polycyclic aromatic compound; the composition comprising 100 parts by weight of a polyamine curable, highly saturated nitrile rubber having an α,β-ethylenically unsaturated nitrile monomer unit, a diene-based monomer unit, an α,β-ethylenically unsaturated dicarboxylic acid monoester monomer unit, and an α,β-ethylenically unsaturated carboxylic acid ester monomer unit other than the α,β-ethylenically unsaturated dicarboxylic acid monoester monomer unit, and having an α,β-ethylenically unsaturated nitrile monomer unit content of 21.0 to 23.0 wt. %, preferably 21.0 to 22.5 wt.
Nok Corporation
06/25/15
20150175715

Process for preparation of a grifola frondosa polysaccharide f2 and its hypoglycemic activity


A grifola frondosa polysaccharide f2 with hypoglycemic activity, process for preparation and use thereof. The process for preparation of grifola frondosa polysaccharide f2 is as follows: the fruit bodies of grifola frondosa were homogenized to a fine powder and extracted with hot water.
Guangdong Yuewei Edible Fungi Technology Co., Ltd.
06/25/15
20150175643

Oligosaccharide-protein conjugates


Provided herein are conjugates comprising a protein and an oligosaccharide of one of formulae i-vi. Also provided herein are pharmaceutical compositions comprising such conjugates.
Genzyme Corporation
06/25/15
20150175636

Method for the synthesis of n-(phosphonomethyl)glycine


A method for the synthesis of n-(phosphonomethyl)glycine or one of its derivatives selected from the group consisting of its salts, its phosphonate esters, or its phosphonate ester salts, which includes the steps of: a) forming, in the presence an acid catalyst, a reaction mixture having 2,5-diketopiperazine, formaldehyde and a compound including one or more p-0-p anhydride moieties, the moieties having one p atom at the oxidation state (+iii) and the other p atom at the oxidation state (+iii) or (+v), to form n,n′-bisphosphonomethyl-2,5-diketopiperazine, its mono- to tetra phosphonate esters, the dehydrated forms of n,n′-bisphosphonomethyl-2,5-diketopiperazine and the phosphonate esters of its dehydrated forms; and b) hydrolysing the n,n′-bisphosphonomethyl-2,5-diketopiperazine, its dehydrated forms or their phosphonate esters to obtain n-(phosphonomethyl)glycine or one of its derivatives selected from the group consisting of its salts, its phosphonate esters and its phosphonate ester salts.. .
Straitmark Holding Ag
06/25/15
20150175635

Method for the synthesis of n-(phosphonomethyl)glycine


The present invention is related to a new method for the synthesis of n-(phosphonomethyl)glycine or one of its derivatives selected from the group consisting of its salts, its phosphonate esters and its phosphonate ester salts, comprising the steps of: a) forming a reaction mixture comprising an acid catalyst, n,n′-bis(carboxymethyl)-2,5-diketopiperazine and a compound comprising one or more p—o—p anhydride moieties, wherein said moieties comprise one p atom at the oxidation state (+111) and the other p atom at the oxidation state (+111) or (+v), to form n,n′-bis(phosphonomethyl)-2,5-diketopiperazine, its dehydrated forms or their phosphonate esters; b) hydrolyzing the reaction mixture to form n-(phosphonomethyl)glycine or one of its derivatives selected from the group consisting of its salts, its phosphonate esters and its phosphonate ester salts.. .
Straitmark Holding Ag
06/25/15
20150175573

Heteroaromatic compounds and their use as dopamine d1 ligands


And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mci, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .
06/25/15
20150175484

Additive including polycarboxylic copolymer and cement composition comprising the same


Disclosed are an additive for cement compositions that includes a polycarboxylic copolymer and a cement composition including the same and, more particularly, an additive for cement compositions that includes a polycarboxylic copolymer and/or a salt thereof, wherein the polycarboxylic copolymer is a copolymer of a monomer mixture including an alkoxy polyalkylene glycol mono(meth)acrylic acid ester-based monomer, a (meth)acrylic acid-based monomer, a (meth)acrylic acid ester-based monomer, and a polyoxyalkylene alkenyl ether sulfate salt and a cement composition including the same.. .
Lg Chem, Ltd.
06/25/15
20150174302

Compositions and methods for coating implant surfaces to inhibit surgical infections


Infection-inhibiting compositions suitable for coating surfaces of implantable medical implants, including compositions and devices for coating medical devices in the operating room prior to implantation in a patient. Methods for inhibiting infection at the site of implantation of an orthopedic device in a human or animal subject, comprise rubbing a surface of the device, prior to implantation, with an infection-inhibiting composition having a waxy matrix comprising an infection-inhibiting material selected from the group consisting of a lipid, an antimicrobial agent, and mixtures thereof, wherein a thin layer of the infection-inhibiting material is deposited on the surface of the device.
Biomet Manufacturing, Llc
06/25/15
20150174300

Block copolymer comprising at least one polyester block and at least one poly(ethylene glycol) block


The present invention provides a block copolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same.. .
Abbott Cardiovascular Systems Inc.
06/25/15
20150174253

Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent


A composition comprising: a benefit agent; at least one polymer including a poly(monostearoyl glycerol-co-succinate) polymer; at least one lower alcohol; and at least one co-solvent; and a method for enhancing topical delivery of a benefit agent are disclosed.. .
Mcneil-ppc, Inc.
06/25/15
20150174210

Potentiation of glucose elimination


Methods related to the treatment of diabetes and improving the efficiency of insulin utilization are provided. The method enables effective control of prandial glucose levels while reducing the risk of postprandial hypoglycemia.
Mannkind Corporation
06/25/15
20150174209

Insulin-pramlintide compositions and methods for making and using them


In alternative embodiments, the invention provides formulations, pharmaceutical compositions, devices and other products of manufacture comprising a therapeutically effective mixture of an insulin and a pramlintide, and methods for making and using them. For example, methods and compositions of the invention are used in the treatment or amelioration of a diabetes, a dementia or alzheimer's disease, any abnormality of blood glucose control, an inability to control blood glucose, an elevation of fasting glucose or impaired fasting glucose (ifg), an abnormality of tolerance to a glucose load or impaired glucose tolerance (igt), a hyperglycemia induced by an illness, a trauma, a medication administration or a form of metabolic, psychological or physical stress, or a hyperglycemia induced by steroids (steroid-induced diabetes), a latent autoimmune diabetes in adults (lada), a postprandial or reactive hypoglycemia or an insulin resistance, a polycystic ovary syndrome (pcos), a ketoacidosis, a gestational diabetes, a hyperkalemia, a cancer or cachexia, a beta blocker overdose, or a jaundice.
Gruppo Biomed Mod
06/25/15
20150174198

Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein


The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with f and hn, which are envelope glycoproteins of sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis.
Dnavec Corporation
06/25/15
20150174164

Nutritional supplement containing phospholipid-dha derived from eggs


Described herein are manufactured dietary supplements that contain a phospholipid extract derived from eggs and the extract contains two forms of phospholipid-docosahexanoic acid derived from eggs. One form of phospholipid-docosahexanoic acid is phosphatidylcholine-docosahexanoic acid, and another form of phospholipid-docosahexanoic acid is phosphatidylethanolamine-docosahexanoic acid.
06/25/15
20150174152

Fat binder obtained from biomass resulting from beer production


The present invention provides a polysaccharide rich composition comprising beta-glucan, chitin and chitosan, extracted from the cell wall of saccharomyces cerevisiae from the by-product biomass resulting from a brewing process, the process for obtaining it and the uses thereof. The composition exerts, among other biofunctionalities, a selective fat binding effect so it is useful in the prevention and/or treatment of a disorder such as overweight, obesity, hypercholesterolemia, hypertriglyceridemia, blood hypertension and cardiovascular disorders.
S.a. Damm
06/25/15
20150173674

Detecting and communicating health conditions


This disclosure provides devices, systems, and methods for detecting physiological parameters, and for communicating information related to the detected physiological parameters to the user, the user's caregiver, and medical personnel. For example, some systems described herein can be configured to detect a user's hypoglycemic event, and to thereafter alert the user, caregivers, and medical personnel to the occurrence of the hypoglycemic event..
Diabetes Sentry Products Inc.
06/25/15
20150173410

Beverage comprising omega fatty acid


Provided herein are drinks (e.g., carbonated drinks) comprising one or more unsaturated fatty acids (e.g., an omega-3, omega-6, and/or omega-9) fatty acids, wherein the drinks are characterized by a low glycemic index and/or an enhanced non-refrigerated shelf life.. .
Change Cola, Inc.
06/25/15
20150173408

Method of producing nanofibrillar cellulose with high absorptivity to fat and cholate


The invention provides a method for making nanofibrillar cellulose with high absorptivity to fat and cholate. According to the invention, dietary fiber material is activated by steam flash explosion and hydrolyzed sequentially by xylanase, laccase and cellulase.
Jiangnan University
06/25/15
20150173397

Pet food composition having probiotic bifidobacterium animalis


A probiotic coated kibble having internal glycerin.. .
The Lams Company
06/25/15
20150173388

Fat and/or oil composition for heat cooking and preparing same


Provided is a fat and/or oil composition for heat cooking containing: a fat and/or oil; and 0.02 to 0.08% by mass of an emulsifying agent. The emulsifying agent is at least one selected from the group consisting of a glyceryl monooleate succinate, a glyceryl monooleate citrate, a polyoxyethylene sorbitan monooleate, a sucrose erucic acid ester, and a fatty acid monoglyceride in which a constituent fatty acid contains 47% by mass or more of a polyunsaturated fatty acid.
The Nisshin Oillio Group, Ltd.
06/25/15
20150173371

Synergistic herbicidal weed control from combinations of 2,4-d-choline and glyphosate


Provided herein are herbicidal compositions comprising a mixture comprising (a) a 2,4-d-choline salt and (b) a salt of n-(phosphonomethyl)glycine (glyphosate). The compositions provide synergistic weed control of undesirable vegetation in areas including, but not limited to, non-crop, fallow-bed, perennial crops, tree, vine and fruit orchards, and plantation crops..
Dow Agrosciences Llc
06/25/15
20150173370

Synergistic herbicidal weed control from combinations of 2,4-d-choline, glyphosate, and glufosinate


Provided herein are herbicidal compositions comprising a mixture comprising (a) the choline salt of 2,4-dichlorophenoxyacetic acid (2,4-d-choline), (b) a salt of n-(phosphonomethyl)glycine (glyphosate), and (c) a salt of 2-amino-4-(hydroxymethylphosphinyl)-butanoic acid (glufosinate). The compositions provide synergistic weed control of undesirable vegetation and improved crop tolerance in 2,4-d-, glyphosate- and glufosinate-tolerant soybeans, corn, or cotton.
Dow Agrosciences Llc
06/25/15
20150173369

Synergistic herbicidal weed control and improved crop tolerance from combinations of 2,4-d-choline, glyphosate, and glufosinate in 2,4-d-, glyphosate- and glufosinate-tolerant soybeans, corn, cotton and other crop areas


Provided herein are herbicidal compositions comprising a mixture comprising (a) the choline salt of 2,4-dichlorophenoxyacetic acid (2,4-d-choline), (b) a salt of n-(phosphonomethyl)glycine (glyphosate), and (c) a salt of 2-amino-4-(hydroxymethylphosphinyl)-butanoic acid (glufosinate). The compositions provide synergistic weed control of undesirable vegetation and improved crop tolerance in 2,4-d-, glyphosate- and glufosinate-tolerant soybeans, corn, or cotton the compositions also provide synergistic weed control of undesirable vegetation in areas including, but not limited to, non-crop, perennial crop, fruiting crop, and plantation crop areas..
Dow Agrosciences Llc
06/25/15
20150173365

Low voc gibberellin formulations


The invention relates to low volatile organic chemical gibberellic acid (“ga3”), gibberellin 4 (“ga4”), gibberellin 4/7 (“ga4/7”), or combinations thereof formulations and methods of their use. Specifically, formulations of the present invention are directed toward agricultural formulations including from about 1 to about 10% of at least one gibberellin selected from the group consisting of ga3, ga4, and ga4/7, from about 85 to about 99% polyethylene glycol with a molecular weight from about 190 to about 420, and from about 0.1 to about 5% of a non-ionic or anionic surfactant, wherein the formulation does not include isopropyl alcohol, and wherein the percentages are percent by weight of the formulation..
Valent Biosciences Corporation
06/25/15
20150173349

Agroformulation comprising copolymer of an amide, polyalkylene glycol (meth)acrylate, and alkyl (meth)acrylate


The present invention provides a composition comprising a pesticide and a copolymer, which contains in polymerized form an amide (monomer a) containing at least one of n-vinyllactame, n—c1-c6 alkyl acrylamide and n,n-di-c1-c6 alkyl acrylamide; a poly(c2-6 alkylene glycol) (meth)acrylate and/or a mono c1-22 alkyl terminated poly(c2-6 alkylene glycol) (meth)acrylate (monomer b); and a c1-c8 alkyl (meth)acrylate (monomer c). Further on, it provides a process for preparing said composition by contacting the pesticide and the copolymer; a method for controlling phytopathogenic fungi and/or unwanted plant growth and/or unwanted insect or mite infestation and/or for regulating the growth of plants, wherein said composition is caused to act on the respective pests, their habitat or the plants to be protected from the respective pest, to the soil and/or to unwanted plants and/or the crop plants and/or their habitat; and a plant propagation material comprising said composition..
Basf Se
06/25/15
20150173330

Mouse model of amyotrophic lateral sclerosis and/or frontotemporal lobar degeneration


To generate an animal model exhibiting symptoms similar to those of human amyotrophic lateral sclerosis and/or human frontotemporal lobar degeneration. An animal model exhibiting symptoms similar to those of human amyotrophic lateral sclerosis and/or human frontotemporal lobar degeneration can be produced by means of generating a mutation in a vertebrate so that expression of a mutant protein with a substitution of tyrosine for alanine at a position corresponding to position 382 of seq id no.
Keio University
06/18/15
20150171496

Lithium air batteries having ether-based electrolytes


A lithium-air battery includes a cathode including a porous active carbon material, a separator, an anode including lithium, and an electrolyte including a lithium salt and polyalkylene glycol ether, where the porous active carbon material is free of a metal-based catalyst.. .
Uchicago Argonne, Llc
06/18/15
20150168415

Compounds and methods for analysis and synthesis of saccharide compounds


Provided is an isotope-labelled compound having a general formula iia′, s-y′-bim, wherein s is a sugar moiety, y′ is an isotope-containing sensor moiety and bim is a benzimidazole. The compound may be used as an agent for saccharide analysis by magnetic resonance spectroscopy (nmr).
Academia Sinica
06/18/15
20150168382

Methods and reagents for evaluating the binding of mammalian sperm


The present invention provides a new apparatus/system for determining fertility of mammalian sperm based on a specific sperm-binding test that mimics sperm binding to an egg. The inventive apparatus/system comprises surface-modified beads with a compound or conjugates containing a carbohydrate sequence associated with the mammalian zona-pellucida (zp) glycoproteins..
The Curators Of The University Of Missouri
06/18/15
20150168371

Serum sample quality determination


A method and device for measuring hil levels in blood serum samples that are disposed in an automated, clinical chemistry analyzer. The device probe can be attached adjacent to a pipette or sample probe of the analyzer and includes fiber optic bundles and a light-reflecting surface.
Siemens Healthcare Diagnostics Inc.
06/18/15
20150166975

Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides


C) a carrier.. .
06/18/15
20150166932

Random intraesterification


The present invention relates to a method for modifying one or more types of triglycerides in a fat, comprising subjecting a single fat selected from the group consisting of high stearic high oleic sunflower oil, high stearic high oleic soybean oil, high stearic high oleic rapeseed oil, high stearic high oleic cottonseed oil, palm olein and shea olein to an intraesterification process in which the fatty acids of the triglycerides of said oil or fat are randomly redistributed between the triglycerides to obtain an oil or fat with a modified solid fat content (sfc) profile. Further, the present invention relates to the obtained fats and use thereof..
Advanta International Bv
06/18/15
20150166930

Reduction of mcpd-compounds in refined plant oil for food


The present invention provides a process for lowering the amount of esters of 2- and 3-mcpd in refined triglyceride oil, wherein said oil prior to entering the process has been treated with one or more refining steps and wherein said oil comprises triglycerides of fatty acids having a carbon chain length of c12-c24 in an amount of at least 50% of the total triglyceride content, the process comprising the steps of: blending the oil with a base and heat treating the oil while passing steam through the oil at reduced pressure, keeping the degree of interesterification in the product from the process below 60%.. .
Aak Ab
06/18/15
20150166811

Polyamine curable, highly saturated nitrile rubber composition


A polyamine curable, highly saturated nitrile rubber composition comprising 100 parts by weight of a polyamine curable, highly saturated nitrile rubber having an α,β-ethylenically unsaturated nitrile monomer unit, a diene-based monomer unit, an α,β-ethylenically unsaturated dicarboxylic acid monoester monomer unit, and an α,β-ethylenically unsaturated carboxylic acid ester monomer unit other than the α,β-ethylenically unsaturated dicarboxylic acid monoester monomer unit, and having an α,β-ethylenically unsaturated nitrile monomer unit content of 22.0 to 24.5 wt. %, preferably 22.5 to 24.5 wt.
Nok Corporation
06/18/15
20150166786

Poly((lactic-co-glycolic acid)-b-lysine) and process for synthesizing a block copolymer of plga and pll (poly-e-cbz-l-lysine)


A method of synthesizing copolymers is provided. The method can include coupling a degradable polymer to a poly(amino acid) and then deprotecting the copolymer if the poly(amino acid) contains protected side chains.
Invivo Therapeutics Corp.
06/18/15
20150166725

N-maleimidyl polymer derivatives


The invention is directed to multi-functional n-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a n-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless n-maleimidyl polymer derivatives..
Nektar Therapeutics
06/18/15
20150166701

Functionalized amphiphilic plant-based polymers


Amphiphilic copolymers formed from plant oil-derived vinyl ether monomers and polyethylene glycol alkyl vinyl ethers are provided. Nanoparticles coated with these amphiphilic polymers are well-suited for water remediation applications..
Ndsu Research Foundation
06/18/15
20150166662

Glycan-modified anti-cd4 antibodies for hiv prevention and therapy


Disclosed herein are glycan-modified anti-cd4 monoclonal antibodies with n-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for hiv prevention and therapy are also disclosed..
06/18/15
20150166656

Monoclonal antibodies to gastrin hormone


The present invention provides monoclonal antibodies (mabs) selective for the n-termini and c-termini of the gastrin hormone forms, gastrin-17 (g17), glycine-extended gastrin-17 (g17-gly), gastrin-34 (g34) and glycine-extended gastrin-34 (g34-gly); and the hybridomas that produce these mabs. Also provided are panels of mabs useful for the detection and quantitation of gastrin-17 (g17), glycine-extended gastrin-17 (g17-gly), gastrin-34 (g34) and glycine-extended gastrin-34 (g34-gly).
Cancer Advances Inc.
06/18/15
20150166628

Selective cartilage therapy


The present invention relates to compositions, methods and kits for delivery of an igf-1 protein or a functional fragment or variant, derivative thereof to cells or tissues that express proteoglycans. More specifically, the present invention relates to fusion proteins comprising a heparin binding protein (hb) comprising seq id no: 1 or seq id no: 2.
Ipsen Bioscience, Inc.
06/18/15
20150166620

Vaccine


The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (x3)mkdx2qlgx1 (seq id no. 99), wherein x1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, x2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine.
Affiris Ag
06/18/15
20150166590

Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof


The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol o-acyltransferase 1 (dgat-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as syndrome x and/or polycystic ovary disease..
Metabasis Therapeutics, Inc.
06/18/15
20150166566

Thienopyridone derivatives useful as activators of ampk


Activators of ampk and therapeutic uses thereof the invention relates to compounds that are direct activators of ampk (amp-activated protein kinase) and their use in the treatment of disorders regulated by activation of ampk. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (nafld), non alcoholic steato-hepatitis (nash), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies..
Poxel
06/18/15
20150166563

Cyclic bridgehead ether dgat1 inhibitors


Useful for treating disorders mediated by acyl coa-diacylglycerol acyl transferase 1 (dgat1), e.g. Metabolic disorders.


Popular terms: [SEARCH]

Gly topics: Door Assembly, Swimming Goggles, Transverse, Alkoxylate, Fluoropolymer, Air Cleaning, Rotor Shaft, Aspect Ratio, Disconnect, Synchronization, Remote Control, Ethylene Glycol, Surfactant, Combustion, Steviol Glycosides

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Gly for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Gly with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.2742

4188

0 - 1 - 88